These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22963676)

  • 1. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer.
    Huo L; Zhang J; Gilcrease MZ; Gong Y; Wu Y; Zhang H; Resetkova E; Hunt KK; Deavers MT
    Histopathology; 2013 Jan; 62(2):267-74. PubMed ID: 22963676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry.
    Huo L; Gong Y; Guo M; Gilcrease MZ; Wu Y; Zhang H; Zhang J; Resetkova E; Hunt KK; Deavers MT
    Histopathology; 2015 Aug; 67(2):245-54. PubMed ID: 25564996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
    Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z
    Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours.
    Provenzano E; Byrne DJ; Russell PA; Wright GM; Generali D; Fox SB
    Histopathology; 2016 Feb; 68(3):367-77. PubMed ID: 26118394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors.
    Takeda Y; Tsuta K; Shibuki Y; Hoshino T; Tochigi N; Maeshima AM; Asamura H; Sasajima Y; Ito T; Matsuno Y
    Arch Pathol Lab Med; 2008 Feb; 132(2):239-43. PubMed ID: 18251583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical Analysis of the Expression of Breast Markers in Basal-like Breast Carcinomas Defined as Triple Negative Cancers Expressing Keratin 5.
    Zombori T; Cserni G
    Pathol Oncol Res; 2018 Apr; 24(2):259-267. PubMed ID: 28470571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors.
    Chia SY; Thike AA; Cheok PY; Tan PH
    Breast; 2010 Oct; 19(5):355-9. PubMed ID: 20347310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
    Yang Y; Lu S; Zeng W; Xie S; Xiao S
    Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
    Lew M; Pang JC; Jing X; Fields KL; Roh MH
    Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer.
    Fritzsche FR; Thomas A; Winzer KJ; Beyer B; Dankof A; Bellach J; Dahl E; Dietel M; Kristiansen G
    Histol Histopathol; 2007 Nov; 22(11):1221-30. PubMed ID: 17647195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
    Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of GATA-3, Mammaglobin and GCDFP-15 Expression in Primary, Metastatic and Triple Negative Breast Carcinomas: An Indian Scenario.
    Rao M; Khade S; Chaudhary R; Singh P; Yadav G; Elhence P; Nalwa A; Sharma R; Goel AD
    Asian Pac J Cancer Prev; 2023 Feb; 24(2):509-515. PubMed ID: 36853299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast.
    Lopez-Bonet E; Pérez-Martínez MC; Martin-Castillo B; Alonso-Ruano M; Tuca F; Oliveras-Ferraros C; Cufí S; Vazquez-Martin A; Beltràn M; Bernadó L; Menendez JA
    Breast Cancer Res Treat; 2011 Feb; 126(1):241-5. PubMed ID: 20978935
    [No Abstract]   [Full Text] [Related]  

  • 14. Markers of metastatic carcinoma of breast origin.
    Gown AM; Fulton RS; Kandalaft PL
    Histopathology; 2016 Jan; 68(1):86-95. PubMed ID: 26768031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin.
    Almási S; Kuthi L; Sejben A; Vörös A; Nagy Á; Zombori T; Cserni G
    Virchows Arch; 2023 May; 482(5):861-868. PubMed ID: 37012444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours.
    Hall RE; Clements JA; Birrell SN; Tilley WD
    Br J Cancer; 1998 Aug; 78(3):360-5. PubMed ID: 9703283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Sensitivities and Specificities of Antibodies to Breast Markers GCDFP-15, Mammaglobin A, and Different Clones of Antibodies to GATA-3: A Study of 338 Tumors Using Whole Sections.
    Kandalaft PL; Simon RA; Isacson C; Gown AM
    Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):609-614. PubMed ID: 26447897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas.
    Liu H; Shi J; Prichard JW; Gong Y; Lin F
    Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups.
    Ni YB; Tsang JY; Chan SK; Tse GM
    Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
    Hafez NH; Shaaban HM
    Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.